tiprankstipranks
Bio-Rad Laboratories (BIO)
NYSE:BIO
US Market
BIO
Bio-Rad Laboratories
RESEARCH TOOLSreports
Want to see BIO full AI Analyst Report?

Bio-Rad Laboratories (BIO) Stock Forecast & Price Target

925 Followers
See the Price Targets and Ratings of:

BIO Analyst Ratings

Hold
4Ratings
Hold
1 Buy
3 Hold
0 Sell
Based on 4 analysts giving stock ratings to
Bio-Rad
Laboratories
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BIO Stock 12 Month Forecast

Average Price Target

$296.25
▼(-0.93% Downside)
Based on 4 Wall Street analysts offering 12 month price targets for Bio-Rad Laboratories in the last 3 months. The average price target is $296.25 with a high forecast of $320.00 and a low forecast of $275.00. The average price target represents a -0.93% change from the last price of $299.02.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"215":"$215","322":"$322","241.75":"$241.8","268.5":"$268.5","295.25":"$295.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":320,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$320.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":296.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$296.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":275,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$275.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[215,241.75,268.5,295.25,322],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,256.55,261.4307692307692,266.3115384615385,271.1923076923077,276.07307692307694,280.95384615384614,285.8346153846154,290.7153846153846,295.59615384615387,300.4769230769231,305.35769230769233,310.23846153846154,315.1192307692308,{"y":320,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,256.55,259.6038461538462,262.65769230769234,265.71153846153845,268.7653846153846,271.8192307692308,274.87307692307695,277.92692307692306,280.9807692307692,284.0346153846154,287.08846153846156,290.14230769230767,293.19615384615383,{"y":296.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,256.55,257.96923076923076,259.38846153846157,260.8076923076923,262.2269230769231,263.6461538461539,265.06538461538463,266.4846153846154,267.90384615384613,269.32307692307694,270.7423076923077,272.16153846153844,273.58076923076925,{"y":275,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":240.43,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":216.56,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":247.99,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":284.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":290.71,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":297.95,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":319.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":321.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.99,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":297.43,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":279.59,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":278.36,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":256.55,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$320.00Average Price Target$296.25Lowest Price Target$275.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on BIO
Tycho Peterson
Jefferies
Jefferies
$275
Hold
-8.03%
Downside
Reiterated
05/21/26
Jefferies Keeps Their Hold Rating on Bio-Rad Laboratories (BIO)
RBC Capital Analyst forecast on BIO
Dan Leonard
RBC Capital
RBC Capital
$320
Buy
7.02%
Upside
Initiated
05/14/26
Bio-Rad resumed with an Outperform at RBC CapitalBio-Rad resumed with an Outperform at RBC Capital
Wells Fargo Analyst forecast on BIO
Brandon Couillard
Wells Fargo
Wells Fargo
$320→$290
Hold
-3.02%
Downside
Assigned
05/01/26
Bio-Rad price target lowered to $290 from $320 at Wells FargoBio-Rad price target lowered to $290 from $320 at Wells Fargo
Citi Analyst forecast on BIO
Patrick B Donnelly
Citi
Citi
$375→$300
Hold
0.33%
Upside
Downgraded
04/07/26
Bio-Rad downgraded to Neutral from Buy at CitiBio-Rad downgraded to Neutral from Buy at Citi
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on BIO
Tycho Peterson
Jefferies
Jefferies
$275
Hold
-8.03%
Downside
Reiterated
05/21/26
Jefferies Keeps Their Hold Rating on Bio-Rad Laboratories (BIO)
RBC Capital Analyst forecast on BIO
Dan Leonard
RBC Capital
RBC Capital
$320
Buy
7.02%
Upside
Initiated
05/14/26
Bio-Rad resumed with an Outperform at RBC CapitalBio-Rad resumed with an Outperform at RBC Capital
Wells Fargo Analyst forecast on BIO
Brandon Couillard
Wells Fargo
Wells Fargo
$320→$290
Hold
-3.02%
Downside
Assigned
05/01/26
Bio-Rad price target lowered to $290 from $320 at Wells FargoBio-Rad price target lowered to $290 from $320 at Wells Fargo
Citi Analyst forecast on BIO
Patrick B Donnelly
Citi
Citi
$375→$300
Hold
0.33%
Upside
Downgraded
04/07/26
Bio-Rad downgraded to Neutral from Buy at CitiBio-Rad downgraded to Neutral from Buy at Citi
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bio-Rad Laboratories

3 Months
Dan LeonardRBC Capital
Success Rate
13/21 ratings generated profit
62%
Average Return
+5.42%
Copying Dan Leonard's trades and holding each position for 3 Months would result in 61.90% of your transactions generating a profit, with an average return of +5.42% per trade.
1 Year
Dan LeonardRBC Capital
Success Rate
10/21 ratings generated profit
48%
Average Return
+4.16%
Copying Dan Leonard's trades and holding each position for 1 Year would result in 47.62% of your transactions generating a profit, with an average return of +4.16% per trade.
2 Years
Dan LeonardRBC Capital
Success Rate
10/21 ratings generated profit
48%
Average Return
-3.54%
Copying Dan Leonard's trades and holding each position for 2 Years would result in 47.62% of your transactions generating a profit, with an average return of -3.54% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BIO Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
0
0
0
0
0
Buy
0
2
2
2
1
Hold
1
2
1
2
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
1
4
3
4
4
In the current month, BIO has received 1 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. BIO average Analyst price target in the past 3 months is 296.25.
Each month's total comprises the sum of three months' worth of ratings.

BIO Financial Forecast

BIO Earnings Forecast

Next quarter’s earnings estimate for BIO is $1.81 with a range of $1.65 to $2.05. The previous quarter’s EPS was $1.89. BIO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BIO has Performed in-line its overall industry.
Next quarter’s earnings estimate for BIO is $1.81 with a range of $1.65 to $2.05. The previous quarter’s EPS was $1.89. BIO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BIO has Performed in-line its overall industry.

BIO Sales Forecast

Next quarter’s sales forecast for BIO is $623.99M with a range of $621.54M to $627.40M. The previous quarter’s sales results were $592.10M. BIO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year BIO has Performed in-line its overall industry.
Next quarter’s sales forecast for BIO is $623.99M with a range of $621.54M to $627.40M. The previous quarter’s sales results were $592.10M. BIO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year BIO has Performed in-line its overall industry.

BIO Stock Forecast FAQ

What is BIO’s average 12-month price target, according to analysts?
Based on analyst ratings, Bio-Rad Laboratories’s 12-month average price target is 296.25.
    What is BIO’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for BIO, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is BIO a Buy, Sell or Hold?
        Bio-Rad Laboratories has a consensus rating of Hold which is based on 1 buy ratings, 3 hold ratings and 0 sell ratings.
          What is Bio-Rad Laboratories’s price target?
          The average price target for Bio-Rad Laboratories is 296.25. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is $320.00 ,the lowest forecast is $275.00. The average price target represents -0.93% Decrease from the current price of $299.02.
            What do analysts say about Bio-Rad Laboratories?
            Bio-Rad Laboratories’s analyst rating consensus is a Hold. This is based on the ratings of 4 Wall Streets Analysts.
              How can I buy shares of BIO?
              Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.